India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE: OGN), a U.S.-based women's healthcare company. If it goes through, the deal that ...

Drug development is notoriously failure-prone. Only one in every ten drug candidates that enter human trials eventually goes onto the market. Turning a promising molecule into a useful medicine ...

Some of the best-selling drugs in the world are facing a loss of exclusivity in key jurisdictions in the upcoming years in what the sector calls "the patent cliff." The need for pharma to top up their ...

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT’s industry-leading events. From the corporate jets of Teterboro Airport to ...

Despite continued uncertainty and mounting regulatory challenges, pharma TV ad spend topped $7 billion through the first 11 months of 2025. Recently released data by iSpot.tv found that the ...

For two decades, the branded pharma website has been treated as the centerpiece of digital engagement. It has been the polished ‘front door’, where brands prepared to tell their story and hoped ...

AFTER AMERICA, China is the world’s largest developer of new medicines. Its companies ran nearly a third of the planet’s clinical trials last year. That is up from just 5% a decade before (see chart 1 ...

Pharmaceutical giants AstraZeneca, Eli Lilly & Co. and Merck & Co. have committed a cumulative $120 million to develop a workforce training center for advanced pharmaceutical manufacturing in Central ...

The average one-year price target for Vicore Pharma Holding AB (OM:VICO) has been revised to 25,50 kr / share. This is an increase of 11.11% from the prior estimate of 22,95 kr dated September 27, ...

Steve Forbes explains how Puerto Rico can once again become a pharmaceutical powerhouse and help to reshore U.S. drug manufacturing. For decades Puerto Rico was one of the world’s premier ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...